📖 行业与公司分析周测（10 题）

Equity Investments

I. Lesson Focus

II. The Problem

An investor is comparing a consumer-electronics company and a pharmaceutical company listed in China. Within limited time, the investor must determine each industry’s cyclicality, competitive structure, barriers to entry, and the durability of each firm’s economic moat before deciding whether a full DCF or relative-valuation model is warranted. Failure to perform a systematic industry-and-company analysis quickly often leads to overpaying for firms at the top of their cycle or missing high-quality companies with durable advantages. This lesson solves that practical problem by reviewing the analytical toolkit and applying it through concrete cases and targeted questions.

III. Industry Analysis Framework

Industry analysis answers three core questions: (1) Where is the industry in its life cycle? (2) What determines its profitability? (3) What are the main growth and risk drivers going forward?

Life-Cycle Stages
- Embryonic: high growth, high risk, negative cash flows
- Growth: rapid revenue increase, intensifying competition, improving cash flows
- Mature: slowing growth, stable competitive structure, abundant free cash flow
- Decline: falling demand, excess capacity, deteriorating margins

Porter’s Five Forces
- Rivalry among existing competitors
- Threat of new entrants
- Threat of substitutes
- Bargaining power of suppliers
- Bargaining power of buyers

The stronger any force, the lower the industry’s long-run average ROE. Industries with high barriers (pharmaceuticals, semiconductor equipment) typically display persistently high ROE above cost of capital.

Industry Structure and Profitability
High concentration (CR5 > 60 %) usually supports elevated gross margins. Cyclical industries (autos, steel, chemicals) exhibit large earnings swings; analysts must monitor capacity utilization and inventory cycles closely.

IV. Company Analysis – Four Integrated Dimensions

After selecting an industry, analysts evaluate the firm across strategy, competitive advantage, financial performance, and valuation consistency.

1. Business Strategy
- Cost leadership versus differentiation (Porter’s generic strategies)
- Degree of vertical integration and supply-chain control

2. Economic Moat Assessment
Sources of moat: brand, patents, network effects, switching costs, economies of scale, regulatory barriers.
Duration: wide moat (>20 years), narrow moat (5–20 years), no moat.
Quantitative signals: sustainable ROE meaningfully above WACC, stable gross margins, high free-cash-flow conversion.

3. Financial-Ratio Framework
- Profitability: gross margin, net margin, ROE (DuPont: ROE = PM × AT × EM)
- Efficiency: days sales outstanding, inventory days, total asset turnover
- Leverage & coverage: interest coverage, net debt/EBITDA
- Cash-flow quality: CFO/NI ratio, capex relative to depreciation

4. Scenario and Sensitivity Analysis
Construct at least three scenarios (optimistic, base, pessimistic) for revenue growth, margins, and capital spending. Valuation must be tested for sensitivity to the most uncertain assumptions.

V. Linking Relative and Absolute Valuation

Relative multiples (forward EV/EBITDA, P/E, P/B, P/S) should be compared with industry peers, historical percentiles, and growth-adjusted benchmarks. In DCF models, terminal value often represents 60–80 % of total enterprise value; therefore the perpetual growth rate g and WACC must be chosen conservatively. Common mistakes include applying historical average multiples to high-growth firms or deriving unrealistically high implied growth rates from elevated P/B ratios of low-ROE companies.

Worked Cases

Case 1: Consumer-Electronics Industry Cycle and Moat Analysis

A consumer-electronics firm reports 28 % revenue growth, 41 % gross margin, and 32 % ROE. Industry CR3 = 68 %. The firm holds two core patents and enjoys high customer switching costs, yet smartphone demand follows a clear 2.5-year replacement cycle.

DuPont decomposition: PM = 12.8 %, AT = 1.05, EM = 2.38 → ROE = 0.128 × 1.05 × 2.38 ≈ 32 %.
Conclusion: The company is in late growth stage with a medium-to-wide moat (patents + switching costs). However, gross margin could fall below 33 % in the next trough. A reasonable forward EV/EBITDA range is 14–16× under the base case.

Case 2: Pharmaceutical Five-Forces Analysis and Sustainable ROE Forecast

An innovative drug company has three blockbuster products with an average 7.2 years of patent life remaining and an R&D-to-sales ratio of 18 %. Barriers to new entrants are very high (clinical trials + regulatory approval), substitute threat is low, yet buyers (hospitals and payers) possess strong bargaining power.

Historical average ROE = 24.6 %, estimated WACC = 9.8 %.
Forecast: After patent cliff and without new launches, ROE declines to ~14 %. With one new blockbuster per year, ROE can be sustained at 19–22 %. Therefore a forward P/E of 25× appears reasonable.

Case 3: Cyclical Industry Relative-Valuation Trap

A steel producer trades at P/B = 0.85 with current ROE = 6 %, while the industry median P/B = 1.4. At first glance the stock looks cheap, yet the firm is at the peak of the cycle (capacity utilization 92 %, inventories elevated).

Normalize ROE at a mid-cycle 11 %. Using g = 2 % and r = 10 %, justified P/B = (0.11 – 0.02) / (0.10 – 0.02) = 1.125.
Conclusion: The current 0.85× P/B still overvalues the firm by 15–20 % at the cycle peak. Valuation should be revisited only after ROE normalizes.

Traps

Key Formulas

• ROE = Net Profit Margin × Asset Turnover × Equity Multiplier (DuPont)
• Sustainable growth rate g = ROE × (1 – dividend payout ratio)
• Justified P/B = (ROE – g) / (r – g)
• Moat test: sustainable ROE – WACC > 5 % maintained for ≥10 years
• Normalized ROE (cyclical) = Normalised EBIT(1–t) / Average invested capital
• Forward EV/EBITDA = Enterprise Value / Expected EBITDA next 12 months

Practice Questions

Q1. Which of the following is least likely to be a source of a wide economic moat?
A. Strong brand recognition
B. Government franchise
C. Short-term patent protection (two years remaining)
D. Significant economies of scale

Q2. An industry has CR5 = 82 %, low supplier concentration, highly differentiated products, and high buyer switching costs. According to Porter’s Five Forces, the industry is most likely to exhibit:
A. Below-average ROE
B. High threat of new entrants
C. Strong profitability
D. Dominant substitute risk

Q3. A consumer-goods company currently earns ROE = 28 %, pays out 35 % of earnings, and has WACC = 9.5 %. Assuming it can sustain the current ROE, its sustainable growth rate is closest to:
A. 9.8 %
B. 18.2 %
C. 28.0 %
D. 35.0 %

Q4. When analyzing a cyclical company, an analyst should focus most on which normalized metric?
A. Current-quarter gross margin
B. ROE based on average capacity utilization over the past five years
C. Current P/E compared with its historical low
D. Latest inventory turnover

Q5. A pharmaceutical firm will lose patent protection on its entire portfolio in three years. Its forward P/E is 32×. Ignoring the new-drug pipeline, the most likely valuation risk is:
A. Undervaluation
B. Overvaluation
C. Fair valuation
D. Cannot be determined

Q6. In a DuPont analysis, net profit margin falls from 12 % to 8 %, asset turnover rises from 1.2 to 1.5, and the equity multiplier is unchanged. ROE will:
A. Increase
B. Decrease
C. Remain the same
D. Cannot be determined

Q7. Which situation provides the strongest evidence of sustainable competitive advantage?
A. ROE consistently above WACC with stable positive free cash flow
B. Revenue growth exceeding the industry average for three consecutive years
C. Gross margin above industry median but highly volatile
D. Largest market capitalization in the industry

Q8. Which approach is least appropriate when valuing a mature regulated utility?
A. Two-stage dividend discount model
B. Assigning a high perpetual growth rate close to GDP growth
C. Close attention to regulatory policy changes
D. Emphasis on interest-coverage ratio under current leverage

Answers

Takeaways

• Always combine Porter’s Five Forces with life-cycle positioning to judge industry profitability durability.
• A firm’s moat width is ultimately measured by how much and how long its ROE exceeds WACC.
• For cyclical companies, normalize ROE and invested capital; never apply peak multiples.
• Patent cliffs, capacity cycles, and disruptive substitutes are the three most common valuation “cliff” risks.
• DuPont decomposition plus cash-flow quality checks are the best tools for spotting earnings manipulation.
• Forward multiples and scenario-based sensitivity tests bridge industry analysis to final valuation conclusions.